This study is for patients with moderate to severe Crohn’s Disease who have failed or are intolerant to one or more anti-TNFα therapies. This study will test the safety and effectiveness of active study drug MEDI2070 against placebo (no study drug) which will be delivered either through intravenous (IV) method, through subcutaneous (under the skin) injections, or using both methods. After 28 weeks, patients will have the opportunity to receive open-label (active study drug) for 24 weeks.
It is hoped that this will help to reduce inflammation (swelling and irritation) within the intestines and relieve symptoms of Crohn’s disease.
Sponsor: MedImmune /Astrazeneca
"GI", Crohn’s Disease, Crohn’s; "CD"; gastrointestinal, "IBD", inflammatory bowel disease